Truist Securities Rates Evolent Health (EVH) buy, $7 Price Target

Truist Securities has reiterated its buy rating on Evolent Health, setting a target price of $7.0, a 48.78% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:11 PM EDT · Updated Jun 18, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Truist Securities rated Evolent Health, Inc. ($EVH) "buy" with a $7 price target on June 12, 2026.

Since the rating, $EVH is down 6.7% after 1 week, up 23.3% after 1 month and down 4.8% to date (from the $4.80 close on Jun 12, 2026).

EVH Evolent Health, Inc.

$4.57 +17.48% year to date

Daily close · Oct 16, 2026

Key Points

Truist Securities reiterated its buy rating on Evolent Health, targeting $7.0, with shares priced at $4.71 on June 12, 2026.
Truist Securities's $7 price target implies 48.78% upside from Evolent Health, Inc.'s ($EVH) current $4.71 share price.
The stock trades significantly below its 52-week high of $9.63, suggesting room for growth as analysts remain optimistic.
Evolent Health has a forward P/E ratio of 9.44 and is expected to report earnings on November 5, 2026.

Get $EVH trade alerts by text

We text you when insiders, Congress or big funds trade $EVH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Evolent Health, Inc. alert may contain errors. Disclosures

Truist Securities Sticks with Buy Rating

Truist Securities has reiterated its buy rating on Evolent Health, Inc. (NYSE: EVH) with a target price of $7.0. This decision comes as the stock was priced at $4.71 on June 12, 2026. The firm believes in the company's potential despite its current trading position.

Comparing Wall Street Ratings

Truist's latest call aligns with a generally positive outlook from other analysts. For instance, JP Morgan maintains an Overweight rating with a target of $6.0, while TD Cowen also keeps a Buy rating with a $6.0 target. Citigroup upgraded its view to Buy with a $6.0 target following a downgrade earlier in July. This suggests that many analysts see Evolent Health as undervalued at its current price.

Stock Performance Context

The stock has been fluctuating below its 52-week high of $9.63 and is currently trading near its 50-day moving average of $4.38. With a market cap of about $417.2 million, Evolent Health's shares have potential for upside if they can reach analysts' targets.

12-month forecast

$EVH price target

Evolent Health, Inc. daily closes and this analyst's $7 target. Not advice.

What Evolent Health, Inc. Does

Evolent Health, Inc. provides specialty care management services across various medical fields, including oncology and cardiology. The company aims to enhance health plan administration through its integrated care management platform, making its performance closely watched by investors.

What’s Next for Evolent Health

Evolent Health is set to report its next earnings on November 5, 2026. As analysts continue to monitor its performance, the upcoming earnings report could provide further insights into its growth and operational health.